GS
BRNS

Gilead Sciences’s Barinthus Biotherapeutics BRNS Stock Holding History

Gilead Sciences’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-99,478
Closed -$92.5K – 11
2025
Q2 		$92.5K Sell
99,478
-270,377
-73% -$236K 0.01% 14
2025
Q1 		$360K Sell
369,855
-250,496
-40% -$257K 0.03% 14
2024
Q4 		$749K Buy
+620,351
New +$722K 0.05% 14

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Gilead Sciences's BRNS Position: Q3 2025 in Review

Gilead Sciences sold out of Barinthus Biotherapeutics (BRNS) in Q3 2025, closing a stake of 99,478 shares — an estimated $92.5K sold.

Gilead Sciences first reported a position in BRNS in Q4 2024 and held it in 3 quarters. The position peaked at $749K in Q4 2024. 15 funds tracked by Wall St. Rank hold BRNS as of Q3 2025.

  • Gilead Sciences reported no remaining Barinthus Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Gilead Sciences sold 99,478 Barinthus Biotherapeutics shares in Q3 2025, an estimated $92.5K.
  • Gilead Sciences first reported a position in Barinthus Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • Gilead Sciences's Barinthus Biotherapeutics position peaked at $749K in Q4 2024.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2025.

Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.